These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11336591)

  • 1. Verteporfin: a milestone in opthalmology and photodynamic therapy.
    Brown SB; Mellish KJ
    Expert Opin Pharmacother; 2001 Feb; 2(2):351-61. PubMed ID: 11336591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserving vision with verteporfin photodynamic therapy.
    Yang YC
    Hosp Med; 2004 Jan; 65(1):39-43. PubMed ID: 14964795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on photodynamic therapy in age-related macular degeneration.
    Rechtman E; Ciulla TA; Criswell MH; Pollack A; Harris A
    Expert Opin Pharmacother; 2002 Jul; 3(7):931-8. PubMed ID: 12083992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin for age-related macular degeneration.
    Messmer KJ; Abel SR
    Ann Pharmacother; 2001 Dec; 35(12):1593-8. PubMed ID: 11793628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology.
    Ophthalmology; 2000 Dec; 107(12):2314-7. PubMed ID: 11186878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration.
    Wickens J; Blinder KJ
    Drug Saf; 2006; 29(3):189-99. PubMed ID: 16524319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New methods of treatment of age-related macular degeneration. Photodynamic therapy. Part I].
    Gierek-Łapińska A; Wykrota H; Trzciakowski K
    Klin Oczna; 2002; 104(3-4):276-82. PubMed ID: 12608319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin ocular photodynamic therapy.
    Bakri SJ; Kaiser PK
    Expert Opin Pharmacother; 2004 Jan; 5(1):195-203. PubMed ID: 14680447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on verteporfin in subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs Aging; 2004; 21(3):203-9. PubMed ID: 14979737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment modalities for age related macular degeneration.
    Das RA; Romano A; Chiosi F; Menzione M; Rinaldi M
    Curr Drug Targets; 2011 Feb; 12(2):182-9. PubMed ID: 20887244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can [symbol: see text] verteporfin help in macular degeneration?
    Drug Ther Bull; 2001 Apr; 39(4):30-2. PubMed ID: 11329798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
    Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.
    Kawczyk-Krupka A; Bugaj AM; Potempa M; Wasilewska K; Latos W; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):161-75. PubMed ID: 25843911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.